lymphocytes. Gene
Therapy 7:2028-2035.
Leucocyte Typing IV (1989). Oxford University Press
Leucocyte Typing III (1987). Oxford University Press
Hogg, N. et al. (1984). Immunol. 53:753.
Linch et al. (1984
497 (1988).
Haziot, A., et al., J. Immunol., 141, 547 (1988).
Hogg, N., et al., Immunology, 53, 753 (1984).
Linch, D. C., et al., Blood, 63, 566 (1984).
Lwin,K. Y., et al., Int. J. Cancer, 36, 433
glycerol.
Molecular mass: ∼59 kDa
Purity: ≥70% (SDS-PAGE, see Figure 1)
Specific Activity: 557–753 nmole/min/mg (see Figure 2)
Precautions and Disclaimer
This product is for R&D use only, not for
glycerol.
Molecular mass: ∼59 kDa
Purity: ≥70% (SDS-PAGE, see Figure 1)
Specific Activity: 557–753 nmole/min/mg (see Figure 2)
Precautions and Disclaimer
This product is for R&D use only, not for
glycerol.
Molecular mass: ∼59 kDa
Purity: ≥70% (SDS-PAGE, see Figure 1)
Specific Activity: 557–753 nmole/min/mg (see Figure 2)
Precautions and Disclaimer
This product is for R&D use only, not for
glycerol.
Molecular mass: ∼59 kDa
Purity: ≥70% (SDS-PAGE, see Figure 1)
Specific Activity: 557–753 nmole/min/mg (see Figure 2)
Precautions and Disclaimer
This product is for R&D use only, not for
glycerol.
Molecular mass: ∼59 kDa
Purity: ≥70% (SDS-PAGE, see Figure 1)
Specific Activity: 557–753 nmole/min/mg (see Figure 2)
Precautions and Disclaimer
This product is for R&D use only, not for
diagnostic procedures.
y Version: 21
Content Version: February 2019
Cat. No. 10 703 753 001 20,000 U
40 U/μl
Store product at −15 to −25°C.
https://www.sigmaaldrich.com
Spectrom., 11(4), 273-282 (2000).
3. Neville, D. et al., Evidence for Phosphorylation of
Serine 753 in CFTR Using a Novel Metal-Ion
Affinity resin and Matrix-assisted Laser Desorption
Mass Spectrometry
defenses against oxidative stress
and some heat-shock proteins in Salmonella typhimurium. Cell 41:753.
16. Stadtman, E. R. (1993) Oxidation of free amino acids and amino acid residues in proteins by
genome editing using ssDNA oligonucleotides with zinc-finger nucleases." Nature
methods 8.9 (2011): 753-755.
Duan, Z., et al. "Lentiviral shRNA screen of human kinases identifies PLK1 as a potential therapeutic
genome editing using ssDNA oligonucleotides with zinc-finger nucleases." Nature
methods 8.9 (2011): 753-755.
Duan, Z., et al. "Lentiviral shRNA screen of human kinases identifies PLK1 as a potential therapeutic
genome editing using ssDNA oligonucleotides with zinc-finger nucleases." Nature
methods 8.9 (2011): 753-755.
Duan, Z., et al. "Lentiviral shRNA screen of human kinases identifies PLK1 as a potential therapeutic
genome editing using ssDNA oligonucleotides with zinc-finger nucleases. Nature Methods. 8(9), 753-5 (2011).
Meyer, M., Ortiz, O., Hrabé, M., Angelis, D., Wurst, W., & Kühn, R. Modeling disease mutations
° to 8°C
The reagents supplied in the kit are sufficient to process 200 samples (5 μL each) on 30 acrylamide gels (7 samples with
derivatized and control reactions; 1.5 mm gel thickness)